NEWARK, Calif. -- BioChain Institute Inc. (“BioChain”), a leader in high-quality processed biosample products and services, and Enable Medicine, a cutting-edge biotechnology company specializing in precision medicine, are pleased to announce their brand-new strategic partnership to advance spatial biology solutions.

The collaboration combines BioChain's extensive experience in biological sample analysis, biospecimens, and advanced molecular diagnostic technologies with Enable Medicine's expertise in generating, managing, and analyzing spatial biology data on its proprietary Enable Cloud Platform. By combining their respective strengths, the two companies aim to revolutionize precision medicine and improve patient outcomes.

Enable Medicine and BioChain are joining hands to provide a comprehensive set of spatial biology tools. The list now includes the Akoya BioSciences proteomics platform, 10x Visium from 10x Genomics, NanoString’s GeoMx, Curio Biosciences’s Slide-seq and Stero-seq from STOmics.

BioChain’s customers now will have access to Enable Medicine’s advanced spatial analysis services, including clustering and neighborhood analysis for 10x Visium.

"We are thrilled to partner with Enable Medicine to advance the field of precision medicine further," says Vidyodhaya Sundaram, Vice President of Business Development at BioChain. "Our combined expertise and resources will allow us to better serve our clients with the most cutting-edge solutions. Via this partnership, we can develop integrated solutions that empower clinicians and researchers to deliver personalized healthcare based on an individual's unique genetic makeup."

BioChain has been at the forefront of providing high-quality products and services, including DNA and RNA extraction kits, PCR reagents, and next-generation sequencing solutions. The company's vast catalog of ethically-sourced tissues has enabled researchers and healthcare professionals worldwide to significantly advance targeted therapies.

Enable Medicine is at the forefront of leveraging protein and genomic data utilizing cutting-edge technologies to develop personalized therapeutics. Their proprietary platform analyzes protein and genomic information to identify specific drivers of diseases, enabling the development of targeted treatments that address the underlying cause of the ailment. Enable Medicine's approach holds immense potential for improving patient outcomes and reducing healthcare costs.

Through this partnership, BioChain and Enable Medicine will collaborate on various initiatives to advance precision medicine. This includes the integration of BioChain's high-quality genomic products and services with Enable Medicine's innovative platform for the development of personalized therapies. By combining their expertise, the two companies aim to accelerate the translation of spatial research into actionable solutions that directly benefit patients.

Sunil Bodapati, CEO of Enable Medicine, commented, "This partnership represents an exciting opportunity to harness the power of genomics and proteomics to deliver targeted therapies for patients. By collaborating with BioChain, we can leverage their extensive experience in genomics research and product development to enhance our precision medicine platform."

Both BioChain and Enable Medicine share a common goal of improving patient care through personalized medicine. This partnership marks a significant step forward in their joint efforts to unlock the full potential of genomics and revolutionize the healthcare industry.

 

About BioChain®

BioChain, a global leader in biological sample analysis, is a biotechnology company based in Newark, California. BioChain has provided the highest-quality biological research tools and services since 1994. With a focus on spatial biology, developed optimized kits and reagents, prepared DNA, RNA, protein lysates, and tissue sections and arrays, BioChain offers a comprehensive range of products and services, including a diverse collection of ethically sourced biospecimens, advanced molecular diagnostic technologies, and innovative solutions for research and development. Committed to excellence, BioChain's ISO-certified facilities ensure the reliability and integrity of its offerings, making it a trusted partner for scientists, researchers, and clinicians worldwide in their pursuit of breakthrough discoveries and improved healthcare solutions. To learn more about BioChain, visit www.biochain.com

 

About Enable Medicine

About Enable Medicine: Enable Medicine is a biotechnology company focused on precision medicine solutions. By leveraging multi-modal data and advanced technologies, Enable Medicine develops targeted therapeutics that address the underlying genetic drivers of diseases. Their mission is to improve patient outcomes and revolutionize the way healthcare is delivered. To learn more about Enable Medicine, visit www.enablemedicine.com

 

Media Contact

Allyson Markey

amarkey@biochain.com

858-442-2167

Talk to an expert

American Society of Human Genetics (ASHG) 2020 Virtual Meeting

BioChain Institute, Inc. is proud to present an abstract at the American Society of Human Genetics (ASHG) 2020 Virtual Meeting.

The ASHG 2020 Virtual Meeting is held on Oct. 27-30, 2020. For more information, please visit ASHG.

Talk to an expert

American Society of Human Genetics (ASHG) 2020 Virtual Meeting

BioChain Institute, Inc. is proud to present an abstract at the American Society of Human Genetics (ASHG) 2020 Virtual Meeting.

The ASHG 2020 Virtual Meeting is held on Oct. 27-30, 2020. For more information, please visit ASHG.

Talk to an expert

American Society of Human Genetics (ASHG) 2020 Virtual Meeting

BioChain Institute, Inc. is proud to present an abstract at the American Society of Human Genetics (ASHG) 2020 Virtual Meeting.

The ASHG 2020 Virtual Meeting is held on Oct. 27-30, 2020. For more information, please visit ASHG.

Talk to an expert

American Society of Human Genetics (ASHG) 2020 Virtual Meeting

BioChain Institute, Inc. is proud to present an abstract at the American Society of Human Genetics (ASHG) 2020 Virtual Meeting.

The ASHG 2020 Virtual Meeting is held on Oct. 27-30, 2020. For more information, please visit ASHG.

Talk to an expert

NGS Webinar

On-Demand Webinar Topic:

 

Gene-Characterized FFPE Tissues for Validation and Discovery on June 9th

 

Register for it and we'll send you the recorded talk!

 

 

This webinar will be pre-recorded for our international customers. A Youtube link will be emailed to you on June 9th to view the webinar.

 

Keep an eye out for it!

 

Please send us questions that you would like to be addressed during the webinar at info@biochain.com

 

Talk to an expert

American Society of Human Genetics (ASHG) 2020 Virtual Meeting

BioChain Institute, Inc. is proud to present an abstract at the American Society of Human Genetics (ASHG) 2020 Virtual Meeting.

The ASHG 2020 Virtual Meeting is held on Oct. 27-30, 2020. For more information, please visit ASHG.

Talk to an expert

AACR Annual Meeting 2018

April 15-18, 2018
McCormick Place North/South
Chicago, Illinois

Join BioChain Institute Inc. at the AACR Annual Meeting 2018 taking place at the McCormick Place North/South in Chicago, Illinois.

The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. Attendees are invited to stretch their boundaries, form collaborations, attend sessions outside their own areas of expertise, and learn how to apply exciting new concepts, tools, and techniques to their own research.

Stop by our booth with any questions or contact us to set up a time to meet while in Chicago. Let’s talk about your upcoming life sciences and oncology projects.

Find out what BioChain has to offer in the way of tissues, DNA, RNA, protein extracts to the biopharma and research communities (including NGS-characterized tumor sections). BioChain also provides kits and instrumentation for nucleic acid purification that are suitable for liquid biopsy and other purposes.

Talk to an expert

BioChain Introduces New Lines of HPV and Microsatellite instability (MSI) Characterized FFPE Tissue Products

To expand its characterized tissue product line, BioChain proudly introduces HPV Characterized and MSI Characterized FFPE tissue products.

FFPE HPV Characterized

HPV infection has been reported to correlate with several cancer types, especially squamous cell carcinomas originating from head and neck (H&N) as well as cervix tissues. HPVs are classified by genotype, and at least 130 types have been identified by sequencing the gene encoding the major capsid protein L1. High-risk genotypes 16 and 18 are associated with 70% of cervical, and about 80% HPV positive vulval and vaginal carcinoma. Using Diacarta’s QuantiVirus HPV E6/E7 RNA test, BioChain offers HPV-characterized H&N and cervix squamous cell carcinoma tissue sections from various donors as control slides for scientists in this field of study.  Both positive and negative samples are available. Please follow the link below to learn more.

https://www.biochain.com/products/tissue/ffpe-hpv-characterized/

FFPE MSI Characterized

Microsatellite instability (MSI) is the condition of genetic hypermutability (predisposition to mutation) that results from impaired DNA mismatch repair (MMR). MSI is associated with a plethora of cancer types, including colorectal, gastric, endometrium, ovarian, hepatobiliary tract, urinary tract, brain, and skin cancers. However, MSI is most prevalent in association with colon cancer. BioChain has characterized many of these cancer samples using either direct PCR or indirect immunohistochemistry (IHC) with MLH-1, PMS2, MSH-2, and MSH-6 antibodies to give these control samples to the cancer research community. Please follow the link below to learn more.

https://www.biochain.com/products/tissue/ffpe-msi-characterized/

Webinar Registration (2)

"*" indicates required fields

PERSONAL INFORMATION

BUSINESS INFORMATION

This field is for validation purposes and should be left unchanged.



 

Talk to an expert

American Society of Human Genetics 2019 Annual Meeting

American Society of Human Genetics ASHG 2019

American Society of Human Genetics (ASHG) 2019 Annual Meeting
Booth# 1608
George R. Brown Convention Center
Houston, TX
October 16-18

Join BioChain Institute Inc. at the ASHG 2019 taking place at the George R. Brown Convention Center in Houston, Texas.

The American Society of Human Genetics Annual Meeting is held each fall in a major U.S. or Canadian city and attracts over 7,000 scientific attendees, plus almost 250 exhibiting companies, which makes it the world’s largest gathering of human genetics professionals. It’s all happening at the George R. Brown Convention Center October 16-18, 2019!

Stop by our booth with any questions or contact us to set up a time to meet while in Houston. Let’s talk about your upcoming genetic testing projects.

Find out what BioChain has to offer in the way of DNA, RNA extracts to the human genetics research community. BioChain also provides kits and instrumentation for nucleic acid purification.

 

Webinar Registration (2)

"*" indicates required fields

PERSONAL INFORMATION

BUSINESS INFORMATION

This field is for validation purposes and should be left unchanged.


 

Talk to an expert